Oxcia Receives FDA Orphan Drug Designation for OXC-201
核心洞察
Oxcia AB (搜索) said the FDA has granted Orphan Drug Designation to its drug candidate OXC-201 for the treatment of idiopathic pulmonary fibrosis (搜索).
The decision follows a positive European Medicines Agency (搜索) opinion on ODD for the same candidate a few weeks earlier.
OXC-201 is a first-in-class oral OGG1 (搜索) inhibitor, with clinical studies expected to begin in 2027 to assess safety and biomarker response.
Oxcia AB (搜索) announced on 15 September 2026 that the U.S. Food and Drug Administration (搜索) has granted Orphan Drug Designation to OXC-201 for the treatment of idiopathic pulmonary fibrosis (搜索) (IPF). The decision follows a positive ODD opinion from the European Medicines Agency (搜索) a few weeks earlier. The company said the U.S. market represents approximately 80% of the global market for the indication.
FDA Orphan Drug Designation can provide regulatory support, fee reductions, tax credits for qualified clinical trial costs and up to seven years of U.S. market exclusivity after a potential marketing approval. Oxcia said the combined FDA and EMA designations strengthen the regulatory and commercial position of OXC-201 ahead of upcoming clinical development.
OXC-201 is a first-in-class oral OGG1 (搜索) inhibitor designed to target mechanisms behind inflammation and fibrosis, including effects on oxidative stress. Preclinical studies showed effects on inflammatory and fibrotic disease markers, tissue effects and improved lung function in disease models, with early data also indicating potential to reduce cough and a favorable tolerability profile. Clinical studies are expected to begin in 2027. Oxcia's O2-DDR platform has also produced OXC-101, in clinical development for acute myeloid leukemia (搜索); both candidates hold Orphan Drug Designation from the FDA and EMA.
Source: Cision News